AU2010296307B2 - Pharmaceutical combination for treating tumor - Google Patents

Pharmaceutical combination for treating tumor Download PDF

Info

Publication number
AU2010296307B2
AU2010296307B2 AU2010296307A AU2010296307A AU2010296307B2 AU 2010296307 B2 AU2010296307 B2 AU 2010296307B2 AU 2010296307 A AU2010296307 A AU 2010296307A AU 2010296307 A AU2010296307 A AU 2010296307A AU 2010296307 B2 AU2010296307 B2 AU 2010296307B2
Authority
AU
Australia
Prior art keywords
hydroxy
oxooctahydrocyclopenta
difluoro
heptanoic acid
pyran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010296307A
Other languages
English (en)
Other versions
AU2010296307A1 (en
Inventor
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Publication of AU2010296307A1 publication Critical patent/AU2010296307A1/en
Application granted granted Critical
Publication of AU2010296307B2 publication Critical patent/AU2010296307B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2010296307A 2009-09-16 2010-09-16 Pharmaceutical combination for treating tumor Ceased AU2010296307B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24301909P 2009-09-16 2009-09-16
US61/243,019 2009-09-16
PCT/JP2010/066619 WO2011034210A1 (en) 2009-09-16 2010-09-16 Pharmaceutical combination for treating tumor

Publications (2)

Publication Number Publication Date
AU2010296307A1 AU2010296307A1 (en) 2012-04-05
AU2010296307B2 true AU2010296307B2 (en) 2016-02-11

Family

ID=43730802

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010296307A Ceased AU2010296307B2 (en) 2009-09-16 2010-09-16 Pharmaceutical combination for treating tumor

Country Status (17)

Country Link
US (3) US9084815B2 (enExample)
EP (1) EP2477632A4 (enExample)
JP (2) JP5891168B2 (enExample)
KR (1) KR101760963B1 (enExample)
CN (2) CN107050458A (enExample)
AR (1) AR078182A1 (enExample)
AU (1) AU2010296307B2 (enExample)
BR (1) BR112012005896A2 (enExample)
CA (1) CA2772314A1 (enExample)
IL (1) IL218392A (enExample)
MX (1) MX2012003188A (enExample)
NZ (1) NZ598618A (enExample)
RU (2) RU2016103415A (enExample)
SG (2) SG10201405467PA (enExample)
TW (1) TWI535436B (enExample)
WO (1) WO2011034210A1 (enExample)
ZA (1) ZA201201894B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US20150099802A1 (en) * 2013-10-03 2015-04-09 Sucampo Ag Selective tumor treatment

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
CA2039420C (en) 1990-04-04 1996-12-10 Ryuji Ueno Treatment of cataract with 15-keto-prostaglandin compounds
ATE148344T1 (de) 1990-04-27 1997-02-15 R Tech Ueno Ltd Verwendung von 15-dehydroxy-16-oxoprostaglandin bei der behandlung von allergischen erkrankungen
US5302617A (en) 1990-04-27 1994-04-12 Kabushikikaisha Ueno Seiyaku Oyo Kenkyuio Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
US5578643A (en) 1992-05-20 1996-11-26 Loyola University Of Chicago Protective prostaglandins for use in conjunction with chemotherapeutic agents
US5438075A (en) * 1993-03-30 1995-08-01 Skubitz; Keith M. Oral glutamine to reduce stomatitis
RU2071780C1 (ru) * 1993-10-11 1997-01-20 Научно-производственное предприятие "Фармэк" Способ лечения медикаментозных эзофаго-гингиво-стоматитов
JPH0770054A (ja) 1993-08-30 1995-03-14 R Tec Ueno:Kk 生化学的拮抗および疾患処置剤
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
DK0857718T3 (da) 1996-06-10 2002-12-16 Sucampo Ag Endothelinantagonist
ATE428429T1 (de) 2000-03-24 2009-05-15 Sucampo Ag Prostaglandine zur behandlung von lichtstrahlung erzeugten augenerkrankungen wie photoretinitis
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
WO2005002588A1 (en) * 2003-07-03 2005-01-13 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
US8202909B2 (en) 2005-01-27 2012-06-19 Sucampo Ag Method for treating central nervous system disorders
CN101180096B (zh) * 2005-03-21 2015-04-22 苏坎波公司 用于治疗粘膜疾病的方法和组合物
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAITO S. ET AL, CHIRYOGAKU, 1990, VOL 24, NO 9, PAGES 117-119 *

Also Published As

Publication number Publication date
TWI535436B (zh) 2016-06-01
KR20120081139A (ko) 2012-07-18
JP5891168B2 (ja) 2016-03-22
KR101760963B1 (ko) 2017-07-24
MX2012003188A (es) 2012-04-30
AU2010296307A1 (en) 2012-04-05
TW201116277A (en) 2011-05-16
ZA201201894B (en) 2012-11-28
CN107050458A (zh) 2017-08-18
IL218392A0 (en) 2012-04-30
IL218392A (en) 2016-05-31
SG179153A1 (en) 2012-04-27
CN102481302A (zh) 2012-05-30
US9084815B2 (en) 2015-07-21
BR112012005896A2 (pt) 2016-03-15
US20110064748A1 (en) 2011-03-17
RU2577700C2 (ru) 2016-03-20
AR078182A1 (es) 2011-10-19
EP2477632A4 (en) 2013-06-12
NZ598618A (en) 2014-10-31
US20170079986A1 (en) 2017-03-23
EP2477632A1 (en) 2012-07-25
JP2016056191A (ja) 2016-04-21
RU2016103415A (ru) 2018-11-22
SG10201405467PA (en) 2014-10-30
US20150272961A1 (en) 2015-10-01
JP2013504520A (ja) 2013-02-07
RU2012114771A (ru) 2013-10-27
WO2011034210A1 (en) 2011-03-24
CA2772314A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
CA2444103C (en) Composition for treating drug-induced constipation with 15-keto-prostaglandins
AU2002251554A1 (en) Composition for Treating Drug-Induced Constipation
JP2010532314A (ja) Ｎｓａｉｄおよびプロスタグランジン化合物の医薬的組み合わせ
AU2010296307B2 (en) Pharmaceutical combination for treating tumor
WO2015050277A1 (en) Selective tumor treatment
CA2691102C (en) Pharmaceutical combination of opioid and prostaglandin compound
US20100305203A1 (en) Method for modulating claudin mediated functions
US8569279B2 (en) Method for modulating claudin mediated functions
WO2016067620A1 (en) Method and composition for treating nonerosive reflux disease
WO2013161973A1 (en) Method for treating irritable bowel syndrome with diarrhea
EP2701709A1 (en) Method for modulating ion transporter
WO2016203317A1 (en) Pharmaceutical compositions comprising fatty acid derivative

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired